A new study, published in the November 2007 issue of Psychiatry 20071 found that the once daily formulation of SEROQUEL XL® in adult patients with schizophrenia significantly reduces the risk of psychotic relapse. The study was scheduled to last one year or until relapse, but significant differences in the relapse rate between active treatment and placebo required the study to be stopped early. Seroquel XL is currently not licensed in the UK and is known as Seroquel XR"! in the rest of the world.
Once-Daily SEROQUEL XL(R) Prevents Relapse In Patients With Schizophrenia Clear Long-term Benefit Leads To Early Completion Of Study
0 comments :
Post a Comment